Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing for Coronavirus


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
Roche SARS-CoV-2 molecular test for PCR testing is effective for both symptomatic and asymptomatic Covid individuals

Roche announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cobas SARS-CoV-2 Nucleic acid test for use on the cobas® Liat® System. This singleplex test is the first real-time reverse transcriptase-polymerase chain reaction (RT-PCR) test that can identify SARS-CoV-2 infection within 20 minutes.

The cobas SARS-CoV-2 test is the first RT-PCR test that screens within 20 minutes both asymptomatic and symptomatic persons, enabling quick, informed decisions at the point of care. The test is for use at a wide range of point-of-care settings, including but not limited to emergency and primary care, physician offices and screening locations, enabling greater access for patients. At launch, the test will also be available in markets accepting the CE mark.

"We learn more about COVID-19 every day and Roche continues to develop solutions that will help healthcare systems around the world slow and eventually defeat this pandemic. We are pleased that we can now provide a test to enable healthcare professionals to identify both asymptomatic and symptomatic infected individuals at the point of care," said Ian Parfrement, Head of Point of Care for Roche Diagnostics Solutions. "Preventing further spread of the virus is crucial for public health and the continued safe reopening of our communities worldwide."

Individuals infected with the SARS-CoV-2 virus may not always show symptoms of COVID-19.1 However, they can still spread the infection, which is why a test that can be used to screen asymptomatic people is important in the fight against the virus. The test offers broad strain coverage of SARS-CoV-2 variants providing further reassurance with clinician-care decisions.

The test will be available in July.

About the cobas Liat System

Utilising PCR technology, the cobas Liat System fully automates the testing process, simplifies workflow and enables healthcare providers to perform molecular testing in a variety of point-of-care settings with speed, reliability and minimal training. Definitive results are generated in 20 minutes or less to aid in patient care decisions. In addition to the existing tests for SARS-CoV-2 & influenza A/B, influenza A/B & RSV, Strep A and C. diff, assays for other infectious diseases are in development. More information is available at www.cobasliat.com.

The cobas Liat System is commercially available in select markets.

Tags : #Roche #SarsCov2 #FDAApproval #FDANews #PCRTest #Asymptotic

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

ACT Fibernet Collaborates with Amazon Prime to Offer Prime Lite Benefits to Consumers June 19, 2025
CARE Hospitals Conducts “The Power of 3” Public Awareness Drive at Punjagutta JunctionJune 19, 2025
Legalising key population led health services in Thailand is a gamechangerJune 19, 2025
MGM Healthcare Successfully Performs Rare Endoscopic Skull Base Surgery on a 1-Year-Old with Brain Herniation inside NoseJune 19, 2025
Asian Paints’ Apcolite All Protek redefines the Gold Standard in Interior Paints with Breakthrough ‘Lotus Effect Technology’June 19, 2025
The Soft Touch of Tomorrow: Rural India's Lives Are Being Changed by 3D-Printed LimbsJune 19, 2025
QNET India Celebrates International Yoga Day with Curated Wellness EssentialsJune 18, 2025
illumine Raises $2.5M Seed Funding to Globally Scale Vertical AI Platform for Childcare ManagementJune 18, 2025
Mykare Achieves EBITDA-Positive Status in Elective Surgery Vertical with 80% Revenue GrowthJune 18, 2025
HCG Manavata Cancer Centre Launches Scalp Cooling Therapy To Prevent Chemotherapy-Induced Hair LossJune 18, 2025
Biohacking in India: From Blue Light Glasses to Metabolic TrackingJune 18, 2025
AI-Generated Prescriptions: Will They Ever Be Safe Enough?June 18, 2025
The Role of Panchayats in Public Health: Untapped Potential in Rural GovernanceJune 18, 2025
When Medicines Stop Working: How Communities in India Are Fighting BackJune 18, 2025
Archish Fertility & IVF, India’s First 100% Fully Transparent Fertility Lab, Partners with Amaha Health for Holistic Patient Support & Mental WellbeingJune 17, 2025
Supporting Mental Health in AutismJune 17, 2025
New guidelines for monitoring IBD patients to prevent bowel cancerJune 17, 2025
TTK Prestige Launches Tri-Ply Hexamagic Cookware, Blending Non-Stick Innovation with Triply DurabilityJune 17, 2025
Turning ₹2.35 Crore of Grant into ₹17.9 Crore of Impact: How Villgro-360 ONE’s Capital For Impact is Benefitting Thousands of Marginalised FarmersJune 17, 2025
Online Chikitsa Mitra Rolls Out Mobile App for Specialized, In-Home HealthcareJune 17, 2025